

Sub 1
23. A method for preventing retinal ganglion cell death comprising the step of administration to the ganglion optic nerve of a mammal, a pharmaceutical composition which evokes a biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure.

24. The method of claim 23 wherein the compound having non-inactivating sodium channel blocking activity is selected from the group consisting of benzothiazole riluzole, phenyl benzothiozole and lifarizine.

A2
25. The method of treatment of claim 24 wherein the composition is an ophthalmic solution adapted from administration to the eye of a mammal in the form of intracameral injection.

Sub 1
26. The method of treatment of claim 23 wherein the ophthalmic composition the concentration of the compound having non-inactivating sodium channel blocking activity is in the range of approximately 0.0001 to 1 percent weight by volume.

REMARKS

The present amendment to the specification is made to correlate the present application with parent applications. No New matter has been added.

In addition, claims 23-26 have been added to define the invention as a method for preventing retinal ganglion cell death comprising the step of administering to the ganglion optic nerve of a mammal, a pharmaceutical composition which evokes a biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure. Support for this